Drug Trial Radar · NCT07377578
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
394
Planned (sponsor's estimate)
Start
Feb 5, 2026
Primary completion
May 30, 2031
Study completion Jan 30, 2033
Sponsor
- Lead sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits both covalent (irreversible) and non-covalent (reversible) binding. This unique dual mechanism of action has shown promising efficacy and a favorable safety profile across various B-cell NHL subtypes in prior Phase 1 and 2 studies. This is a Phase 3, randomized, open-label study comparing Rocbrutinib versus investigator's choice of BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib) in patients with MCL who have received at least one prior line of therapy and are naïve to BTK inhibitor treatment (except for intolerance).
Conditions
- Mantle Cell Lymphoma
Interventions
RocbrutinibDrug
Rocbrutinib at 150 mg once daily orally until disease progression or unacceptable toxicity
IbrutinibDrug
Ibrutinib, 560 mg once daily orally and continuously
AcalabrutinibDrug
Acalabrutinib, 100 mg twice daily orally and continuously
ZanubrutinibDrug
Zanubrutinib, 160 mg twice daily orally and continuously
OrelabrutinibDrug
Orelabrutinib, 150 mg once daily orally and continuously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by IRCTime frame: approximately 30 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.